Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Progenitor cell combination normalizes retinal vascular development in the oxygen-induced retinopathy (OIR) model.

Li Calzi S, Shaw LC, Moldovan L, Shelley WC, Qi X, Racette L, Quigley JL, Fortmann SD, Boulton ME, Yoder MC, Grant MB.

JCI Insight. 2019 Nov 1;4(21). pii: 129224. doi: 10.1172/jci.insight.129224.

2.

Mousetap, a Novel Technique to Collect Uncontaminated Vitreous or Aqueous and Expand Usefulness of Mouse Models.

Fortmann SD, Lorenc VE, Shen J, Hackett SF, Campochiaro PA.

Sci Rep. 2018 Apr 23;8(1):6371. doi: 10.1038/s41598-018-24197-2.

3.

AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration.

Liu Y, Fortmann SD, Shen J, Wielechowski E, Tretiakova A, Yoo S, Kozarsky K, Wang J, Wilson JM, Campochiaro PA.

Mol Ther. 2018 Feb 7;26(2):542-549. doi: 10.1016/j.ymthe.2017.12.002. Epub 2017 Dec 8.

4.

Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System.

Cherepanov V, Fortmann SD, Hyun Kim M, Marciniak TA, Litvinov O, Mihalev K, Serebruany VL.

Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):69-71. doi: 10.1093/ehjcvp/pvx038. No abstract available. Erratum in: Eur Heart J Cardiovasc Pharmacother. 2018 Jul 1;4(3):189.

PMID:
29272379
5.

Reversible retinal vessel closure from VEGF-induced leukocyte plugging.

Liu Y, Shen J, Fortmann SD, Wang J, Vestweber D, Campochiaro PA.

JCI Insight. 2017 Sep 21;2(18). pii: 95530. doi: 10.1172/jci.insight.95530. eCollection 2017 Sep 21.

6.

Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?

Serebruany VL, Fortmann SD, Hanley DF, Kim MH.

Am J Ther. 2017 Mar/Apr;24(2):e139-e143. doi: 10.1097/MJT.0000000000000395. Review.

PMID:
28267691
7.

The Nicotinic Cholinergic Pathway Contributes to Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity.

Hackett SF, Seidel C, Abraham S, Chadha R, Fortmann SD, Campochiaro PA, Cooke JP.

Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):1296-1303. doi: 10.1167/iovs.16-20670.

8.

Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths.

Serebruany VL, Fortmann SD, Cherepanov V, Litvinov O, Kim MH, Marciniak TA.

Am J Med. 2017 Jun;130(6):e245-e246. doi: 10.1016/j.amjmed.2016.12.037. Epub 2017 Feb 1. No abstract available.

PMID:
28161342
9.

Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.

Silva RLE, Kanan Y, Mirando AC, Kim J, Shmueli RB, Lorenc VE, Fortmann SD, Sciamanna J, Pandey NB, Green JJ, Popel AS, Campochiaro PA.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaai8030. doi: 10.1126/scitranslmed.aai8030.

10.

The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization.

Zeng M, Shen J, Liu Y, Lu LY, Ding K, Fortmann SD, Khan M, Wang J, Hackett SF, Semenza GL, Campochiaro PA.

J Mol Med (Berl). 2017 Apr;95(4):417-429. doi: 10.1007/s00109-016-1498-9. Epub 2016 Dec 21.

11.

Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation.

Serebruany VL, Fortmann SD, Rao SV, Tanguay JF, Lordkipanidze M, Hanley DF, Can M, Kim MH, Marciniak TA.

Thromb Haemost. 2016 May 2;115(5):905-10. doi: 10.1160/TH15-11-0882. Epub 2016 Feb 18. Review.

PMID:
26887783
12.

Vorapaxar and optimal aspirin dose: The FDA outlook.

Serebruany VL, Fortmann SD, Kim MH.

Int J Cardiol. 2016 Jan 15;203:903-5. doi: 10.1016/j.ijcard.2015.11.064. Epub 2015 Nov 10. Review.

PMID:
26609688
13.

Vorapaxar for secondary stroke prevention: perspectives and obstacles.

Serebruany VL, Kim MH, Fortmann SD, Hanley DF.

Expert Rev Neurother. 2015;15(12):1377-82. doi: 10.1586/14737175.2015.1111761. Epub 2015 Nov 13.

PMID:
26566105
14.

Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar.

Serebruany VL, Fortmann SD, Kim MH.

Cardiology. 2016;133(2):69-72. doi: 10.1159/000440798. Epub 2015 Oct 22.

PMID:
26488178
15.

The FDA report on vorapaxar in the elderly: A convoluted dilemma.

Serebruany VL, Fortmann SD.

Int J Cardiol. 2015 Dec 15;201:601-3. doi: 10.1016/j.ijcard.2015.08.177. Epub 2015 Aug 28.

PMID:
26340124
16.

International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic?

Serebruany VL, Fortmann SD.

Expert Rev Cardiovasc Ther. 2015;13(8):867-9. doi: 10.1586/14779072.2015.1063419. Epub 2015 Jun 28.

PMID:
26118636
17.

Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics".

Serebruany VL, Fortmann SD.

Thromb Haemost. 2014 Jul 3;112(1):4-9. doi: 10.1160/TH13-10-0862. Epub 2014 May 8.

PMID:
24816578
18.

Thrombin generation and platelet reactivity at hospital discharge and 6-month outcome after the acute coronary syndrome in diabetic and nondiabetic patients.

Kuliczkowski W, Szewczyk M, Kaczmarski J, Sztohryn E, Greif M, Pres D, Fortmann SD, PoloĊ„ski L, Serebruany V.

Cardiology. 2014;128(1):25-33. doi: 10.1159/000356492. Epub 2014 Feb 7.

PMID:
24514756
19.

Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.

Serebruany VL, Pokov AN, Fortmann SD, DiNicolantonio JJ.

Thromb Haemost. 2014 Jan;111(1):3-7. doi: 10.1160/TH13-08-0631. Epub 2013 Nov 28.

PMID:
24285121

Supplemental Content

Loading ...
Support Center